In tumors, CDK4 and CDK6 may be selectively required for oncogenic proliferation as described for CDK4 in breast cancer [11] and melanoma [12], or CDK6 in MLL-rearranged acute myeloid leukemia (AML) [13]. This evidence concerns the gene CDK4 and breast carcinoma.